title: Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells.
abstract: DNA topoisomerase inhibitors, camptothecin and 4'-demethylepipodophyllotoxin ethylidene-beta-D-glucoside (VP16) had strong differentiation-inducing activity for all five kinds of leukemia cells examined (human HL60, U937, ML1, and K562 cells and mouse M1 cells) as judged from measurements of various differentiation markers. The characteristics that appeared as a result of differentiation induced by these inhibitors were essentially similar in every cell line. Exposure to VP16 for 2 h induced both differentiation and DNA-strand breaks in K562 cells, whereas podophyllotoxin, which lacks topoisomerase II inhibitory activity, induced neither differentiation nor DNA-strand breaks in these cells. These results suggest a parallelism between the induction of differentiation and that of DNA-strand breaks. The combination of VP16 and recombinant tumor necrosis factor alpha (rTNF alpha) synergistically induced differentiation of human U937, ML1, and M1 cells and had an additive effect on HL60 cells. Simultaneous treatment with rTNF alpha plus camptothecin or VP16, or pretreatment with camptothecin or VP16, followed by rTNF alpha induced marked differentiation of M1 cells. These results indicate that inhibition of topoisomerase (either topoisomerase I or II) followed by the action of rTNF alpha was effective in inducing differentiation of leukemia cells.
authors.affiliation: School of Pharmaceutical Sciences, Showa University, Tokyo.
authors.forename: K
authors.initials: K
authors.lastname: Nakaya
authors.forename: S
authors.initials: S
authors.lastname: Chou
authors.forename: M
authors.initials: M
authors.lastname: Kaneko
authors.forename: Y
authors.initials: Y
authors.lastname: Nakamura
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor; D002166:Camptothecin / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D004247:DNA / Q000187:drug effects; D004249:DNA Damage; D004357:Drug Synergism; D005047:Etoposide / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D051379:Mice; D013997:Time Factors; D059004:Topoisomerase I Inhibitors; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D014408:Biomarkers, Tumor; D059004:Topoisomerase I Inhibitors; D014409:Tumor Necrosis Factor-alpha; D005047:Etoposide; D004247:DNA; D002166:Camptothecin